Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C-PF-06651600 · 1 trial · 1 indication
Cumulative recovery (%) of radioactivity in urine.
Cumulative recovery (%) of radioactivity in feces
| Arm | Type | Description |
|---|---|---|
| Period A | EXPERIMENTAL | Single oral dose of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF 06651600). |
| Period B | EXPERIMENTAL | Single oral dose of 200 milligrams (mg) unlabeled PF-06651600 followed at time of peak plasma concentration (Tmax) by an Intravenous (IV) dose of 60 micrograms.14C -PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF-06651600). |
| Name | Type | Description |
|---|---|---|
| 14C-PF-06651600 | DRUG | Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity |
| 14C-PF-06651600 IV | DRUG | IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity |
| PF-06651600 | DRUG | Oral solution 200mg |
Inclusion Criteria: * Male participants who are healthy as determined by medical evaluation including a detailed medical history, full physical examination, including blood pressure (BP) and pulse rate (PR) measurement, 12 lead ECG, and clinical laboratory tests. * Body mass index (BMI) of 17.5 to ...
14C-PF-06651600 is a carbon-14 radiolabeled small molecule developed by Pfizer, Inc. (ticker PFE) for use in a Phase 1 clinical study. It is a radiolabeled form of PF-06651600 used to study how the drug is absorbed, distributed, metabolized, and excreted in the human body.
14C-PF-06651600 is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer conducted the clinical research on this radiolabeled compound.
14C-PF-06651600 is in Phase 1 clinical development. It is an investigational compound and has not been approved by the FDA. The single Phase 1 trial evaluating it has been completed.
14C-PF-06651600 was evaluated in one Phase 1 trial, NCT03929510, titled a study to characterize absorption, distribution, metabolism and excretion of 14C PF-06651600 and to evaluate the absolute oral bioavailability and fraction absorbed of PF-06651600. The trial enrolled 6 healthy male volunteers in the Netherlands and is completed.
14C-PF-06651600 is used as a radiolabeled research compound in a Phase 1 clinical study of healthy volunteers. The study characterized its absorption, distribution, metabolism, and excretion, and evaluated the absolute oral bioavailability and fraction absorbed of PF-06651600. No therapeutic indication has been disclosed.
The Phase 1 trial of 14C-PF-06651600, NCT03929510, enrolled 6 participants. It was a controlled study in healthy male volunteers aged 18 years and older, conducted in the Netherlands, and it is now completed.